Howard I Scher

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:8253-61. 2005
  2. doi request reprint Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
  3. pmc Considerations in the development of circulating tumor cell technology for clinical use
    David R Parkinson
    New Enterprise Associates, Menlo Park, CA 94025, USA
    J Transl Med 10:138. 2012
  4. pmc Validation and clinical utility of prostate cancer biomarkers
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Clin Oncol 10:225-34. 2013
  5. ncbi request reprint Increased survival with enzalutamide in prostate cancer after chemotherapy
    Howard I Scher
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 367:1187-97. 2012
  6. pmc Identification of novel androgen receptor target genes in prostate cancer
    Unnati Jariwala
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Mol Cancer 6:39. 2007
  7. ncbi request reprint The association between measures of progression and survival in castrate-metastatic prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:1488-92. 2007
  8. ncbi request reprint Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
  9. ncbi request reprint Prostate carcinoma: defining therapeutic objectives and improving overall outcomes
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:758-71. 2003
  10. pmc Prostate cancer clinical trial end points: "RECIST"ing a step backwards
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:5223-32. 2005

Collaborators

Detail Information

Publications109 found, 100 shown here

  1. ncbi request reprint Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:8253-61. 2005
    ..On the basis of this schema, we discuss strategies that are focused on the AR either directly or indirectly, as single agents or in combination, that are in clinical development...
  2. doi request reprint Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  3. pmc Considerations in the development of circulating tumor cell technology for clinical use
    David R Parkinson
    New Enterprise Associates, Menlo Park, CA 94025, USA
    J Transl Med 10:138. 2012
    ....
  4. pmc Validation and clinical utility of prostate cancer biomarkers
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Clin Oncol 10:225-34. 2013
    ..We also highlight the requirements of analytical validation, the sequence of trials needed for clinical validation and regulatory approval, and the future outlook for imaging and CTC biomarkers...
  5. ncbi request reprint Increased survival with enzalutamide in prostate cancer after chemotherapy
    Howard I Scher
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 367:1187-97. 2012
    ..We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy...
  6. pmc Identification of novel androgen receptor target genes in prostate cancer
    Unnati Jariwala
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Mol Cancer 6:39. 2007
    ..The androgen receptor (AR) plays critical roles in both androgen-dependent and castrate-resistant prostate cancer (PCa). However, little is known about AR target genes that mediate the receptor's roles in disease progression...
  7. ncbi request reprint The association between measures of progression and survival in castrate-metastatic prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:1488-92. 2007
    ..To explore the association between progression-free survival and overall survival time in patients with castration-resistant prostate cancer treated with microtubule-targeted therapies...
  8. ncbi request reprint Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  9. ncbi request reprint Prostate carcinoma: defining therapeutic objectives and improving overall outcomes
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:758-71. 2003
    ..Proving the benefit of these approaches requires a series of unique trials with unique endpoints relevant to the clinical state of the patients and the specific therapy under evaluation...
  10. pmc Prostate cancer clinical trial end points: "RECIST"ing a step backwards
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:5223-32. 2005
    ..To relate clinical issues to the clinical manifestations of prostate cancers across disease states using the eligibility and outcome criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST)...
  11. ncbi request reprint Bicalutamide for advanced prostate cancer: the natural versus treated history of disease
    H I Scher
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2928-38. 1997
    ..To determine the therapeutic effects of bicalutamide 200 mg in patients with prostate cancers of different hormone sensitivities...
  12. doi request reprint Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
    Howard I Scher
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 29:2191-8. 2011
    ..To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial...
  13. pmc Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
    Daniel C Danila
    Department of Medicine, Joan and Sanford E Weill College of Medicine of Cornell University, Ithaca, NY, USA
    J Clin Oncol 28:1496-501. 2010
    ..This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy...
  14. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  15. pmc End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:3695-704. 2011
    ..We also discuss circulating tumor cells measured with the CellSearch assay, recently cleared by the FDA for monitoring CRPC...
  16. pmc Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics
    Howard I Scher
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6634-40. 2011
    ..The use of such an adaptive approach to clinical trial design has the potential to greatly improve the field of oncology and facilitate the development of personalized medicine...
  17. ncbi request reprint Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Department of Medicine, Joan and Sanford I Weill College of Medicine, New York, New York 10021, USA
    Endocr Relat Cancer 11:459-76. 2004
    ..We propose that treatment regimes combining AAT with direct AR targeting strategies may provide a more complete blockade of androgen signaling, thereby preventing or significantly delaying the emergence of treatment-resistant disease...
  18. pmc Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
    Karen A Autio
    Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:3186-94. 2013
    ..The toxicity and efficacy when each agent is combined at full, recommended doses, in a repetitive fashion is not well established...
  19. pmc Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 49:1066-74. 2008
    ..An analysis was performed to assess lesion detectability by (111)In-J591 gamma-camera imaging compared with standard imaging methods and the effect of increasing antibody mass on lesion detectability, biodistribution, and dosimetry...
  20. ncbi request reprint Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:1842-8. 2003
    ..To improve the therapeutic efficacy and reduce the toxicity of TEC, the authors substituted intravenous (i.v.) EMP for oral EMP based on single-agent studies demonstrating an improved safety profile with i.v. EMP...
  21. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  22. doi request reprint Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Matthew D Galsky
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2147-54. 2008
    ..This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704...
  23. pmc TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
    Daniel C Danila
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 60:897-904. 2011
    ..AA treatment results in dramatic declines in prostate-specific antigen (PSA) in some patients and no declines in others, suggesting the presence of molecular determinants of sensitivity in tumors...
  24. ncbi request reprint A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 56:1921-30. 2007
    ..No impact on PSA slope was detected. We address the relevance of the multivalent approach for prostate cancer treatment...
  25. ncbi request reprint Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
    Daniel C Danila
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:7053-8. 2007
    ..We evaluated the association of baseline circulating tumor cell (CTC) number with clinical characteristics and survival in patients with castrate metastatic disease considered for different hormonal and cytotoxic therapies...
  26. ncbi request reprint Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 64:90-4. 2004
    ..To describe the 5-year outcomes of patients with high-risk localized prostate cancer treated with neoadjuvant estramustine and vinblastine followed by concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)...
  27. ncbi request reprint Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:834-9. 2006
    ..To analyze post-androgen depletion (AD) primary tumors to identify markers of treatment failure because AD does not reduce the probability of prostate-specific antigen (PSA) failure after prostatectomy...
  28. pmc Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
    Sven Wenske
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 124:659-63. 2009
    ..720 to 0.726, p=0.2). fPSA is routinely measured during prostate cancer detection. We suggest that the role of fPSA in aiding preoperative prediction should be investigated in further cohorts...
  29. ncbi request reprint A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Michael J Morris
    Department of Medicine Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:2378-83; discussion 2383-4. 2007
    ..We defined the antitumor effects of bortezomib alone and in combination with prednisone in patients with progressive, castration resistant metastatic prostate cancer...
  30. ncbi request reprint Rapid androgen cycling as treatment for patients with prostate cancer
    David Feltquate
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:7414-21. 2006
    ..To investigate the safety and feasibility of rapid androgen cycling for men with progressive prostate cancer...
  31. pmc Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Elizabeth R Dennis
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:519-24. 2012
    ..Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure...
  32. doi request reprint Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease
    Michael J Donovan
    Aureon Laboratories, Yonkers, New York, NY, USA
    BJU Int 105:462-7. 2010
    ....
  33. ncbi request reprint Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
    ..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
  34. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  35. pmc Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Clin Cancer Res 11:3210-6. 2005
    ..We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve as an outcome measure for patients with castrate metastatic prostate cancer treated with antimicrotubule chemotherapy...
  36. ncbi request reprint Hsp90 as a therapeutic target in prostate cancer
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:709-16. 2003
    ..These data suggest that inhibitors of Hsp90 may represent a novel strategy for the treatment of patients with prostate cancer and clinical trials to test this hypothesis are currently ongoing...
  37. doi request reprint A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
    Dana Rathkopf
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:181-9. 2010
    ....
  38. ncbi request reprint 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy
    Heiko Schoder
    Department of Radiology Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:4761-9. 2005
    ..We calculated sensitivity and specificity of PET and correlated PET findings with PSA values, other clinical parameters, and conventional imaging, when available...
  39. ncbi request reprint Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial
    David Andrew Verbel
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Urology 61:142-4. 2003
    ..The size of this interval is dependent on the sample size used. This report illustrates the use of a published method that accounts for this uncertainty and aids in the decision to proceed to a definitive trial...
  40. ncbi request reprint Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer
    Michael J Morris
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 59:913-8. 2002
    ....
  41. ncbi request reprint Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 11:1983-9. 2005
    ..Furthermore, we hypothesized that intermittent dosing would allow for dose escalation and greater inhibition of EGFR-dependent antiapoptotic pathways...
  42. ncbi request reprint Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
    Curr Urol Rep 6:163-70. 2005
    ..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development...
  43. ncbi request reprint Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
    ..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2...
  44. pmc A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
    Gopa Iyer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 69:1089-97. 2012
    ....
  45. pmc ARN-509: a novel antiandrogen for prostate cancer treatment
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 72:1494-503. 2012
    ..Our findings offer preclinical proof of principle for ARN-509 as a promising therapeutic in both castration-sensitive and castration-resistant forms of prostate cancer...
  46. ncbi request reprint Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer
    Francis M Sirotnak
    Program in Molecular Pharmacology and Therapeutics and Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3870-6. 2002
    ..The effect of ZD1839 was also examined in combination with either bicalutamide ("Casodex") or cytotoxic agents against a hormone-dependent or -independent variant of CWR22, respectively...
  47. pmc Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:1775-82. 2007
    ..To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules...
  48. ncbi request reprint High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:1868-75. 2004
    ..Pulse-dosed calcitriol and dexamethasone may maximize tolerability and efficacy. The authors examined the toxicity of pulse-dosed calcitriol with zoledronate and with the addition of dexamethasone at the time of disease progression...
  49. pmc Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 56:237-44. 2009
    ..Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth...
  50. ncbi request reprint A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 23:3114-22. 2005
    ..Compared with a subsequent trial with the same bivalent vaccine plus QS-21 at the maximal tolerated dose of 100 microg, the 5000 microg dose of GPI-0100 produced comparable antibody titers...
  51. ncbi request reprint Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7454-61. 2005
    ..The relationship among dose, safety, pharmacokinetics, and antibody-dependent cellular cytotoxicity (ADCC) activation for unlabeled J591 has not been explored...
  52. pmc Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer
    Gustavo S P Meirelles
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 16:6093-9. 2010
    ..To compare the diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET) and bone scans (BS) in the assessment of osseous lesions in patients with progressing prostate cancer...
  53. pmc Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  54. pmc Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination
    Polly D Gregor
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 116:415-21. 2005
    ..These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth...
  55. pmc Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy
    Timothy J Judson
    Weill Cornell Medical College, New York, NY, USA
    J Clin Oncol 31:2580-5. 2013
    ..Prior evidence suggests good patient compliance with reporting at scheduled clinic visits, but there is limited evidence about compliance with long-term longitudinal reporting between visits...
  56. ncbi request reprint Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  57. ncbi request reprint Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 54:694-702. 2005
    ..The results justify the inclusion of TF(c) at a dose of 1 microg as a relevant antigenic target in a multivalent phase II vaccine trial in patients in the high-risk minimal disease state...
  58. ncbi request reprint Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen
    Kathleen Beekman
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Urology 65:947-52. 2005
    ..Long-term follow-up of trials incorporating androgen-deprivation with local therapy have shown improved survival relative to local therapy alone. This suggests that the benchmark for treatment of minimal metastatic disease can be cure...
  59. pmc Prostate cancer topography and patterns of lymph node metastasis
    Yuji Tokuda
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 34:1862-7. 2010
    ....
  60. doi request reprint Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer
    Susan F Slovin
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 7:E77-82. 2009
    ..The secondary endpoint was to assess the efficacy of cetuximab in combination with doxorubicin as well as to determine the optimal biologic dose and the maximum tolerated dose...
  61. pmc Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer
    Margaret A Leversha
    Molecular Cytogenetics Core Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 15:2091-7. 2009
    ....
  62. pmc Susceptibility loci associated with prostate cancer progression and mortality
    David J Gallagher
    Department of Medicine, Clinical Genetics Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, New York, New York 10065, USA
    Clin Cancer Res 16:2819-32. 2010
    ..Prostate cancer is a heterogeneous disease with a variable natural history that is not accurately predicted by currently used prognostic tools...
  63. ncbi request reprint DNA vaccines: an active immunization strategy for prostate cancer
    Jedd D Wolchok
    Clinical Immunology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:659-66. 2003
    ..We are currently conducting a phase I trial of human and mouse PSMA DNA vaccines in patients with recurrent prostate cancer, based on preclinical experiments described below...
  64. doi request reprint Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer
    Jorge A Carrasquillo
    Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Nucl Med Mol Imaging 40:1384-93. 2013
    ..We conducted a study to better profile the pharmacokinetics, pharmacodynamics, and biodistribution of this agent...
  65. ncbi request reprint Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
    David B Solit
    Department of Medicine, Program in Cell Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 63:2139-44. 2003
    ..These results suggest that Hsp90 inhibitors can effectively suppress Akt activity in animal models of human cancer at nontoxic doses, thus sensitizing tumor cells to proapoptotic stimuli...
  66. pmc Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors
    Nicholas Mitsiades
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 72:6142-52. 2012
    ....
  67. pmc Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival
    Pauliina Helo
    Departments of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Chem 55:765-73. 2009
    ..e., prostate-specific antigen (PSA)] and KLK2 mRNAs. We also assessed the association of CTCs with disease characteristics and survival...
  68. ncbi request reprint Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids
    Richard Enmon
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 63:8393-9. 2003
    ..These results suggest that significant gains in treatment effectiveness may be obtained by combining these treatment modalities, warranting additional preclinical investigation...
  69. ncbi request reprint HER-2 profiling and targeting in prostate carcinoma
    Michael J Morris
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 94:980-6. 2002
    ..This study explored the feasibility of molecular profiling to determine the correlation between HER-2 expression, hormonal sensitivity, and the antitumor effects of trastuzumab and paclitaxel in patients with prostate carcinoma...
  70. pmc Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel
    Gretchen A Gignac
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:966-74. 2008
    ..PFS, however, is vulnerable to inter-study design variability. The authors sought to identify and quantify this variability and the resultant error in PFS across prostate cancer clinical trials...
  71. pmc TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy
    Anuradha Gopalan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:1400-6. 2009
    ....
  72. ncbi request reprint CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
  73. ncbi request reprint Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
    Oren Smaletz
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3972-82. 2002
    ..To develop a pretreatment prognostic model for survival of patients with progressive metastatic prostate cancer after castration using parameters that are measured during routine clinical management...
  74. pmc Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer
    Dana Rathkopf
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:880-7. 2011
    ..A first-in-man phase I study was conducted to define the safety and tolerability of oral BMS-641988 in patients with castration-resistant prostate cancer (CRPC)...
  75. ncbi request reprint Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8669-73. 2005
    ....
  76. ncbi request reprint Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events
    F M Sirotnak
    Department of Medicine, Program of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Carcinog 41:150-63. 2004
    ....
  77. ncbi request reprint Prostate cancer: a dynamic illness with shifting targets
    David R Shaffer
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 4:407-14. 2003
    ..Directed approaches must account for this changing dynamic so that clinical outcomes may be improved...
  78. ncbi request reprint Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements
    Gunnar Steineck
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Acta Oncol 41:668-74. 2002
    ..The results support the use of cytotoxic drugs in the relapsed setting and definitive trials are ongoing to prove any benefit to survival...
  79. ncbi request reprint Advances in imaging in the postoperative patient with a rising prostate-specific antigen level
    Hedvig Hricak
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:616-34. 2003
    ..Another modality offering information about anatomy and metabolism of the local disease is PET/CT. The value of PET/CT at present is controversial, but new studies exploring the role of PET/CT in aggressive prostate cancer are promising...
  80. ncbi request reprint 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts
    David B Solit
    Program in Cell Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:986-93. 2002
    ....
  81. ncbi request reprint Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer
    Rodolfo Nunez
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 43:46-55. 2002
    ..Our aim was to detect the proportion of bone and soft-tissue lesions that represent metabolically active tumor sites in patients with progressive metastatic prostate cancer...
  82. pmc Integrative genomic profiling of human prostate cancer
    Barry S Taylor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Cell 18:11-22. 2010
    ..The genomic and clinical outcome data from these patients are now made available as a public resource...
  83. ncbi request reprint Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  84. pmc Improved prediction of prostate cancer recurrence through systems pathology
    Carlos Cordon-Cardo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Invest 117:1876-83. 2007
    ..This robust platform has broad applications in patient diagnosis, treatment management, and prognostication...
  85. pmc Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI)
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Pain Symptom Manage 41:558-65. 2011
    ....
  86. ncbi request reprint Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, 10021, New York, NY, USA
    Crit Rev Oncol Hematol 46:S21-31. 2003
    ..High-throughput preclinical assays of gene expression are being developed to enhance selection of drug sequences and combinations for clinical testing...
  87. pmc NF-kappaB regulates androgen receptor expression and prostate cancer growth
    Liying Zhang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA
    Am J Pathol 175:489-99. 2009
    ..In addition, levels of both NF-kappaB and AR were strongly correlated in human prostate cancer. Our data suggest that NF-kappaB can regulate AR expression in prostate cancer and that NF-kappaB inhibitors may have therapeutic potential...
  88. ncbi request reprint Quantifying the amount of variation in survival explained by prostate-specific antigen
    David A Verbel
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2576-9. 2002
    ..Using a population-based approach, we explore the relationship between PSA and survival and generate a measure to demonstrate the amount of the variation in survival explained by PSA...
  89. ncbi request reprint Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:826-31. 2005
    ..To identify predictors of distant metastases (DM) among patients who develop an isolated prostate-specific antigen (PSA) relapse after definitive external-beam radiotherapy for clinically localized prostate cancer...
  90. ncbi request reprint Clinical approaches to osseous metastases in prostate cancer
    Michael J Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 8:161-73. 2003
    ..Treatments directed against bone disease have the potential both to palliate pain and to increase survival...
  91. ncbi request reprint Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Med Decis Making 27:380-6. 2007
    ..By adjusting for patient risk, this method can provide a more precise assessment of phase 2 treatment efficacy, thereby improving the decision whether to proceed to a phase 3 clinical trial...
  92. pmc Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing
    Andrew J Vickers
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:972-6. 2007
    ..We sought to determine the proportion of phase II trials that require historical data to establish the null and to determine how these historical estimates were derived...
  93. pmc The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pain Med 11:337-46. 2010
    ..When finalized, it may provide a blueprint for evaluations of PRO measures that can be considered by sponsors and investigators involved in PRO research and drug registration trials...
  94. ncbi request reprint Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
    David R Shaffer
    Genitourinary Oncology Service, Immunicon Corporation, Huntingdon Valley, Pennsylvania, USA
    Clin Cancer Res 13:2023-9. 2007
    ..We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer...
  95. pmc Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
    ..Many of these strategies are currently being tested in clinical trials in CRPC...
  96. pmc Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
    Bradley J Beattie
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 51:183-92. 2010
    ....
  97. ncbi request reprint Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer
    William D Fox
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Clin Cancer Res 8:3226-31. 2002
    ..We administered 5 mg/kg rhu alpha VEGF i.p. twice weekly as a single agent and together with paclitaxel to established CWR22R xenografts...
  98. ncbi request reprint Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
    D Andrew Loblaw
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 25:1596-605. 2007
    ..To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa)...
  99. ncbi request reprint Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
    Julie L Eiseman
    Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 13:2121-7. 2007
    ..Pretreatment plasma samples were also obtained from 12 healthy volunteers. Plasma IGFBP-2 and Her-2 ECD concentrations were quantitated by ELISA...
  100. ncbi request reprint Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
    J Clin Oncol 25:675-81. 2007
    ..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...
  101. ncbi request reprint Prostate-specific antigen as a marker of disease activity in prostate cancer
    Alan W Partin
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Oncology (Williston Park) 16:1218-24; discussion 1224, 1227-8 passim. 2002
    ..Part 2 of this two-part article, which began in the August issue, discusses the role of PSA in hormonal and drug therapies and in primary and secondary chemoprevention...